Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy

Detalles Bibliográficos
Autores principales: Rinaldi, Francesca, Federle, Lisa, Puthenparampil, Marco, Perini, Paola, Grassivaro, Francesca, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Clinical/Scientific Notes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730817/
https://www.ncbi.nlm.nih.gov/pubmed/29259997
http://dx.doi.org/10.1212/NXI.0000000000000420
_version_ 1783286415311765504
author Rinaldi, Francesca
Federle, Lisa
Puthenparampil, Marco
Perini, Paola
Grassivaro, Francesca
Gallo, Paolo
author_facet Rinaldi, Francesca
Federle, Lisa
Puthenparampil, Marco
Perini, Paola
Grassivaro, Francesca
Gallo, Paolo
author_sort Rinaldi, Francesca
collection PubMed
description
format Online
Article
Text
id pubmed-5730817
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-57308172017-12-19 Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy Rinaldi, Francesca Federle, Lisa Puthenparampil, Marco Perini, Paola Grassivaro, Francesca Gallo, Paolo Neurol Neuroimmunol Neuroinflamm Clinical/Scientific Notes Lippincott Williams & Wilkins 2017-12-13 /pmc/articles/PMC5730817/ /pubmed/29259997 http://dx.doi.org/10.1212/NXI.0000000000000420 Text en Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical/Scientific Notes
Rinaldi, Francesca
Federle, Lisa
Puthenparampil, Marco
Perini, Paola
Grassivaro, Francesca
Gallo, Paolo
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title_full Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title_fullStr Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title_full_unstemmed Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title_short Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
title_sort evidence of b-cell dysregulation in severe cns inflammation after alemtuzumab therapy
topic Clinical/Scientific Notes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730817/
https://www.ncbi.nlm.nih.gov/pubmed/29259997
http://dx.doi.org/10.1212/NXI.0000000000000420
work_keys_str_mv AT rinaldifrancesca evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy
AT federlelisa evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy
AT puthenparampilmarco evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy
AT perinipaola evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy
AT grassivarofrancesca evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy
AT gallopaolo evidenceofbcelldysregulationinseverecnsinflammationafteralemtuzumabtherapy

Ejemplares similares